NASDAQ:MDCX Medicus Pharma (MDCX) Stock Price, News & Analysis $2.10 -0.14 (-6.25%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Medicus Pharma Stock (NASDAQ:MDCX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medicus Pharma alerts:Sign Up Key Stats Today's Range$2.06▼$2.3050-Day Range$1.97▼$3.4052-Week Range$1.80▼$8.94Volume225,527 shsAverage Volume213,729 shsMarket Capitalization$28.50 millionP/E RatioN/ADividend YieldN/APrice Target$23.50Consensus RatingStrong Buy Company Overview Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. Read More Medicus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreMDCX MarketRank™: Medicus Pharma scored higher than 41% of companies evaluated by MarketBeat, and ranked 618th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingMedicus Pharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedicus Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Medicus Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Medicus Pharma are expected to decrease in the coming year, from ($1.14) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicus Pharma is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicus Pharma is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedicus Pharma has a P/B Ratio of 7.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medicus Pharma's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MDCX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedicus Pharma does not currently pay a dividend.Dividend GrowthMedicus Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for MDCX. News and Social Media2.1 / 5News Sentiment-0.17 News SentimentMedicus Pharma has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Medicus Pharma this week, compared to 2 articles on an average week.Search Interest15 people have searched for MDCX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows11 people have added Medicus Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Medicus Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $579,000.00 in company stock.Percentage Held by Insiders11.20% of the stock of Medicus Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Medicus Pharma's insider trading history. Receive MDCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicus Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCX Stock News HeadlinesMedicus Pharma Ltd to Acquire Antev Ltd in Strategic Expansion MoveAugust 7, 2025 | theglobeandmail.comMedicus Pharma Seeks FDA Fast-Track Approval for Innovative Skin Cancer TreatmentAugust 7, 2025 | theglobeandmail.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 13 at 2:00 AM | Porter & Company (Ad)Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccinesAugust 4, 2025 | proactiveinvestors.comMedicus Pharma Appoints Deloitte for Licensing DealJuly 30, 2025 | tipranks.comMedicus Pharma Ltd. Strengthens Board with New AppointmentsJuly 23, 2025 | tipranks.comMedicus Pharma Ltd. Announces Submission of Type C Meeting Request to ...July 23, 2025 | finanznachrichten.deMedicus Pharma Ltd.: Medicus Pharma Ltd Announces a Definitive ...July 23, 2025 | finanznachrichten.deSee More Headlines MDCX Stock Analysis - Frequently Asked Questions How have MDCX shares performed this year? Medicus Pharma's stock was trading at $2.43 at the beginning of the year. Since then, MDCX shares have decreased by 12.1% and is now trading at $2.1350. How were Medicus Pharma's earnings last quarter? Medicus Pharma Ltd (NASDAQ:MDCX) issued its earnings results on Monday, August, 11th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.04. When did Medicus Pharma IPO? Medicus Pharma (MDCX) raised $4 million in an IPO on Thursday, November 14th 2024. The company issued 1,000,000 shares at $4.13 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital Markets was co-manager. Who are Medicus Pharma's major shareholders? Medicus Pharma's top institutional investors include Interchange Capital Partners LLC (11.69%), Guyasuta Investment Advisors Inc. (0.57%), SeaCrest Wealth Management LLC (0.34%) and May Hill Capital LLC (0.26%). View institutional ownership trends. How do I buy shares of Medicus Pharma? Shares of MDCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2025Today8/13/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MDCX Previous SymbolNASDAQ:MDCX CIK1997296 Webwww.medicuspharma.com Phone732-300-3046FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Medicus Pharma$23.50 High Price Target$27.00 Low Price Target$20.00 Potential Upside/Downside+1,013.7%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-564.51% Return on Assets-290.94% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book7.28Miscellaneous Outstanding Shares13,570,000Free Float12,053,000Market Cap$28.63 million OptionableN/A BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:MDCX) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.